Dr. Reddy’s CEO Seeks To Acquire Global “String Of Pearls”
This article was originally published in PharmAsia News
Executive Summary
Dr. Reddy's Laboratories CEO GV Prasad plans a "string of pearls," companies around the globe it can acquire to expand the firm's presence abroad. In doing so, Dr. Reddy's would leave major acquisitions to others and concentrate instead on branded drugs in the United States and generics and custom pharma services there and in other markets. The company expects the smaller acquisitions to pay off in the medium and long term. The plans are reflected in the company's announcement it would acquire BASF and its U.S. business for $40 million. (Click here for more